Evidence map›Paper›PMID 40185999›Full record

ReviewNature reviews. Chemistry2025

Supramolecular approaches for the treatment of hypoxic regions in tumours.

Irene Regeni, Sylvestre Bonnet

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Nanochirality-programmed type-I photosensitizer enables deep-tumor photodynamic therapy by reducing extracellular-matrix adhesion.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  6. Article
  7. Stimuli-Responsive Supramolecular Biomaterials for Cancer Theranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Irene RegeniLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands. i.regeni@lic.leidenuniv.nl.ORCID 0000-0001-9102-3053
Sylvestre BonnetLeiden Institute of Chemistry, Leiden University, Leiden, The Netherlands. bonnet@chem.leidenuniv.nl.ORCID 0000-0002-5810-3657

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Supramolecular chemistry provides a range of 'weak' intermolecular interactions that allow drugs and prodrugs to self-assemble. In the complex biological setting of blood and tumours, these interactions must be stable enough for efficient and selective drug delivery to the tumour site, but weak enough to allow the release of the cytotoxic load. The non-covalent nature of supramolecular interactions enables the detachment of smaller (pro)drug monomers that can penetrate cancer cells differently to the original nanoparticles. Hypoxic tumours show low oxygen levels due to poor vascularization, which poses challenges for drug delivery and generates biological resistances. Supramolecular building blocks specifically designed for hypoxic tumours offer targeted activation of prodrug self-assemblies, enhancing effectiveness against hypoxic cancer cells and hypoxic regions in tumours. This Review explores how supramolecular chemistry can improve (pro)drug delivery and activation in hypoxic tumours.

Indexed as

Antineoplastic AgentsNeoplasmsProdrugsAnimalsDrug Delivery SystemsHumansNanoparticlesTumor HypoxiaAntineoplastic AgentsProdrugs

Identifiers

PMID40185999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.